Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proctocolectomy, Restorative | 12 | 2025 | 117 | 1.680 |
Why?
|
| Robotic Surgical Procedures | 5 | 2018 | 411 | 1.600 |
Why?
|
| Laparoscopy | 12 | 2022 | 791 | 1.560 |
Why?
|
| Colonic Pouches | 8 | 2025 | 99 | 1.120 |
Why?
|
| Rectum | 4 | 2018 | 150 | 1.090 |
Why?
|
| Rectal Neoplasms | 4 | 2021 | 138 | 1.080 |
Why?
|
| Inflammatory Bowel Diseases | 11 | 2025 | 677 | 1.080 |
Why?
|
| Colitis, Ulcerative | 12 | 2025 | 824 | 1.070 |
Why?
|
| Colon | 4 | 2025 | 562 | 0.930 |
Why?
|
| Robotics | 3 | 2018 | 271 | 0.820 |
Why?
|
| Crohn Disease | 10 | 2025 | 844 | 0.760 |
Why?
|
| Colectomy | 7 | 2025 | 201 | 0.690 |
Why?
|
| Anastomotic Leak | 4 | 2018 | 111 | 0.670 |
Why?
|
| Learning Curve | 2 | 2018 | 25 | 0.640 |
Why?
|
| Colorectal Neoplasms | 5 | 2022 | 1103 | 0.560 |
Why?
|
| Pouchitis | 3 | 2025 | 58 | 0.510 |
Why?
|
| Credentialing | 1 | 2017 | 15 | 0.500 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 146 | 0.500 |
Why?
|
| Surgical Flaps | 2 | 2016 | 252 | 0.490 |
Why?
|
| Rectovaginal Fistula | 1 | 2016 | 7 | 0.480 |
Why?
|
| Rectus Abdominis | 1 | 2015 | 41 | 0.450 |
Why?
|
| Anal Canal | 2 | 2016 | 94 | 0.440 |
Why?
|
| Intestinal Mucosa | 2 | 2016 | 834 | 0.420 |
Why?
|
| Leiomyosarcoma | 1 | 2014 | 48 | 0.400 |
Why?
|
| Postoperative Complications | 11 | 2025 | 2681 | 0.390 |
Why?
|
| Intestines | 2 | 2015 | 441 | 0.360 |
Why?
|
| Retrospective Studies | 22 | 2025 | 10972 | 0.320 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 1211 | 0.270 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 251 | 0.270 |
Why?
|
| Humans | 43 | 2025 | 98076 | 0.270 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 1099 | 0.260 |
Why?
|
| Quality of Life | 2 | 2019 | 1895 | 0.250 |
Why?
|
| Patient Satisfaction | 1 | 2010 | 511 | 0.250 |
Why?
|
| Gastrointestinal Agents | 2 | 2019 | 197 | 0.240 |
Why?
|
| Focal Adhesions | 3 | 2017 | 67 | 0.230 |
Why?
|
| Neutrophils | 2 | 2006 | 346 | 0.230 |
Why?
|
| Adult | 22 | 2025 | 29538 | 0.220 |
Why?
|
| Anastomosis, Surgical | 3 | 2022 | 289 | 0.210 |
Why?
|
| Male | 25 | 2025 | 47075 | 0.210 |
Why?
|
| Treatment Outcome | 10 | 2020 | 9711 | 0.210 |
Why?
|
| Fibronectins | 2 | 2006 | 104 | 0.200 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2003 | 19 | 0.200 |
Why?
|
| Integrin beta1 | 1 | 2003 | 36 | 0.200 |
Why?
|
| Candidiasis | 1 | 2003 | 40 | 0.200 |
Why?
|
| NADPH Oxidases | 1 | 2003 | 87 | 0.190 |
Why?
|
| Hypoalbuminemia | 1 | 2022 | 9 | 0.190 |
Why?
|
| Phenotype | 3 | 2025 | 2638 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2020 | 707 | 0.190 |
Why?
|
| Female | 23 | 2025 | 51535 | 0.180 |
Why?
|
| Malnutrition | 1 | 2022 | 39 | 0.180 |
Why?
|
| Pressure Ulcer | 1 | 2022 | 45 | 0.180 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 4025 | 0.180 |
Why?
|
| Operative Time | 3 | 2018 | 175 | 0.180 |
Why?
|
| Bacterial Infections | 1 | 2003 | 184 | 0.180 |
Why?
|
| Middle Aged | 19 | 2025 | 29427 | 0.170 |
Why?
|
| Debridement | 2 | 2016 | 64 | 0.170 |
Why?
|
| Risk Factors | 8 | 2025 | 6232 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 478 | 0.160 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 21 | 0.160 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.160 |
Why?
|
| Ostomy | 2 | 2020 | 15 | 0.150 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 119 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2019 | 30 | 0.150 |
Why?
|
| Recurrence | 4 | 2021 | 1254 | 0.150 |
Why?
|
| Postoperative Period | 3 | 2021 | 321 | 0.150 |
Why?
|
| Transcriptome | 1 | 2025 | 820 | 0.150 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 63 | 0.140 |
Why?
|
| Sepsis | 1 | 2003 | 427 | 0.140 |
Why?
|
| Colitis | 1 | 2021 | 264 | 0.130 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 582 | 0.130 |
Why?
|
| Thrombospondins | 1 | 2017 | 15 | 0.130 |
Why?
|
| Caveolin 1 | 1 | 2017 | 24 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2017 | 75 | 0.130 |
Why?
|
| Surgeons | 1 | 2022 | 325 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2018 | 186 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 358 | 0.130 |
Why?
|
| Sigmoidoscopy | 1 | 2016 | 36 | 0.120 |
Why?
|
| Ileostomy | 2 | 2019 | 28 | 0.120 |
Why?
|
| Blood Loss, Surgical | 3 | 2013 | 140 | 0.120 |
Why?
|
| Aged | 8 | 2020 | 21758 | 0.110 |
Why?
|
| Perineum | 1 | 2015 | 40 | 0.110 |
Why?
|
| Intestinal Fistula | 1 | 2015 | 32 | 0.110 |
Why?
|
| Appendectomy | 1 | 2015 | 43 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2018 | 4823 | 0.110 |
Why?
|
| Pilot Projects | 2 | 2015 | 977 | 0.110 |
Why?
|
| Cost Savings | 1 | 2015 | 68 | 0.110 |
Why?
|
| Surgical Instruments | 1 | 2015 | 69 | 0.110 |
Why?
|
| Hospitals, University | 1 | 2015 | 192 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 342 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 338 | 0.110 |
Why?
|
| Pelvic Floor | 1 | 2015 | 88 | 0.110 |
Why?
|
| Abdomen | 1 | 2015 | 120 | 0.110 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 85 | 0.110 |
Why?
|
| Enterococcus faecalis | 1 | 2015 | 58 | 0.110 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 97 | 0.110 |
Why?
|
| Young Adult | 7 | 2025 | 7507 | 0.110 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2014 | 20 | 0.100 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 198 | 0.100 |
Why?
|
| Clostridium Infections | 1 | 2016 | 132 | 0.100 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2014 | 37 | 0.100 |
Why?
|
| Prognosis | 5 | 2025 | 4116 | 0.100 |
Why?
|
| Portal Vein | 1 | 2014 | 121 | 0.100 |
Why?
|
| Collagen | 1 | 2015 | 313 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2025 | 1995 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2015 | 391 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2017 | 604 | 0.090 |
Why?
|
| Suture Techniques | 1 | 2013 | 140 | 0.090 |
Why?
|
| Incidence | 2 | 2014 | 1779 | 0.090 |
Why?
|
| Pneumonectomy | 1 | 2014 | 222 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 264 | 0.080 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2014 | 309 | 0.080 |
Why?
|
| Length of Stay | 2 | 2013 | 878 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 255 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2017 | 865 | 0.080 |
Why?
|
| Time Factors | 3 | 2013 | 5567 | 0.080 |
Why?
|
| Microbiota | 1 | 2016 | 467 | 0.080 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 252 | 0.080 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2010 | 52 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 302 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 360 | 0.070 |
Why?
|
| Cross Infection | 1 | 2010 | 155 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2019 | 102 | 0.070 |
Why?
|
| Reoperation | 3 | 2019 | 727 | 0.070 |
Why?
|
| Focal Adhesion Kinase 2 | 2 | 2006 | 12 | 0.070 |
Why?
|
| src-Family Kinases | 2 | 2006 | 70 | 0.060 |
Why?
|
| Paxillin | 2 | 2006 | 59 | 0.060 |
Why?
|
| Illinois | 2 | 2019 | 522 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 1416 | 0.060 |
Why?
|
| Propensity Score | 2 | 2018 | 213 | 0.060 |
Why?
|
| Remission Induction | 2 | 2019 | 754 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2025 | 1565 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2004 | 679 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 3212 | 0.060 |
Why?
|
| Macrophage Activation | 1 | 2004 | 53 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 882 | 0.050 |
Why?
|
| Fluconazole | 1 | 2003 | 11 | 0.050 |
Why?
|
| Peroxides | 1 | 2003 | 13 | 0.050 |
Why?
|
| Abdominal Cavity | 1 | 2003 | 17 | 0.050 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2003 | 31 | 0.050 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2003 | 30 | 0.050 |
Why?
|
| Laparotomy | 1 | 2003 | 64 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2004 | 267 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 313 | 0.050 |
Why?
|
| Colostomy | 1 | 2022 | 14 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2003 | 126 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 219 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 87 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 2006 | 305 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 225 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 127 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2003 | 264 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2003 | 419 | 0.040 |
Why?
|
| Ligands | 1 | 2003 | 486 | 0.040 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 1013 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2003 | 304 | 0.040 |
Why?
|
| Radiography | 1 | 2003 | 764 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 764 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 1009 | 0.040 |
Why?
|
| United States | 3 | 2019 | 8196 | 0.040 |
Why?
|
| Biopsy | 1 | 2003 | 1224 | 0.040 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2019 | 15 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 337 | 0.040 |
Why?
|
| Adolescent | 3 | 2019 | 10079 | 0.030 |
Why?
|
| Vitamin D | 1 | 2021 | 286 | 0.030 |
Why?
|
| Proteins | 1 | 2003 | 804 | 0.030 |
Why?
|
| Ileum | 1 | 2018 | 172 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2019 | 306 | 0.030 |
Why?
|
| Biological Products | 1 | 2019 | 189 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 903 | 0.030 |
Why?
|
| Medical Records | 1 | 2017 | 123 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 525 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 2080 | 0.030 |
Why?
|
| Dehydration | 1 | 2015 | 22 | 0.030 |
Why?
|
| Intraabdominal Infections | 1 | 2015 | 10 | 0.030 |
Why?
|
| Anus Diseases | 1 | 2015 | 16 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1120 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 305 | 0.030 |
Why?
|
| Models, Economic | 1 | 2015 | 62 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 726 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 117 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2015 | 211 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2015 | 304 | 0.030 |
Why?
|
| Endoscopy | 1 | 2018 | 384 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2015 | 144 | 0.030 |
Why?
|
| Contrast Media | 1 | 2019 | 1011 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2015 | 270 | 0.030 |
Why?
|
| Mesenteric Veins | 1 | 2014 | 38 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 916 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 1012 | 0.020 |
Why?
|
| Conversion to Open Surgery | 1 | 2013 | 11 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 993 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 2013 | 0.020 |
Why?
|
| Ischemia | 1 | 2015 | 262 | 0.020 |
Why?
|
| Rectal Diseases | 1 | 2013 | 25 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 523 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2015 | 256 | 0.020 |
Why?
|
| Infliximab | 1 | 2013 | 166 | 0.020 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 661 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 1394 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2585 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 1384 | 0.020 |
Why?
|
| Macrophages | 1 | 2015 | 643 | 0.020 |
Why?
|
| Intestinal Perforation | 1 | 2011 | 38 | 0.020 |
Why?
|
| Chicago | 1 | 2016 | 1513 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1109 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 2483 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2013 | 370 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 540 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1275 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2013 | 424 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 4071 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1764 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 2658 | 0.020 |
Why?
|
| Detergents | 1 | 2006 | 32 | 0.020 |
Why?
|
| Phosphotyrosine | 1 | 2006 | 31 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 3620 | 0.010 |
Why?
|
| Tyrosine | 1 | 2006 | 135 | 0.010 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2004 | 9 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 68 | 0.010 |
Why?
|
| Membrane Microdomains | 1 | 2004 | 52 | 0.010 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2004 | 95 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 106 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2004 | 212 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 291 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2006 | 682 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 446 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 1145 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 423 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 12698 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 28894 | 0.010 |
Why?
|